It’s no secret that 2025 is turning into a tricky year for life science companies looking to raise cash. Political and economic uncertainty has fed through into  a ‘risk-off’ environment.  So, when DeepMind spin-out Isomorphic Labs, a London-based AI drug development company, announced last week (March 31) that it had pocketed a huge $600 million […]